Regeneron Pharmaceuticals, INC Form 4 insider transactions

Regeneron Pharmaceuticals EVP General Counsel and Secretary Joseph J. LaRosa reported the acquisition of restricted stock and stock options, alongside a sale of shares for tax withholding purposes.

Christopher R. Fenimore, EVP Finance CFO of Regeneron Pharmaceuticals, Inc., reported the acquisition of restricted stock and stock options, alongside a disposition of shares for tax purposes.

Regeneron Pharmaceuticals' EVP, General Counsel, and Secretary, Joseph J. LaRosa, exercised stock options and subsequently disposed of shares for tax obligations.

Regeneron Pharmaceuticals Director Bonnie L. Bassler exercised stock options and sold an equal number of common shares under a pre-arranged 10b5-1 plan.

Regeneron Pharmaceuticals' VP Controller, Jason Pitofsky, sold 431 shares of common stock at $651.43 per share.

Regeneron Pharmaceuticals Director Christine A. Poon exercised stock options and subsequently sold a portion of her common stock holdings in late October 2025.

Regeneron Pharmaceuticals' EVP of Research, Andrew J. Murphy, exercised stock options and subsequently sold shares for tax withholding and gifting purposes.

Regeneron Pharmaceuticals director David P. Schenkein acquired 166 shares of common stock and 1,958 stock options on January 2, 2025.

Director Craig B. Thompson reports acquisition of restricted stock units and stock options in Regeneron Pharmaceuticals.

Director N. Anthony Coles reports acquisition of Regeneron stock and options via grant.

Director Huda Y. Zoghbi reports acquisition of Regeneron stock and stock options.

Director Arthur F. Ryan reports acquisition of Regeneron stock and options on January 2, 2025.

Director Christine Poon reports acquisition of common stock and stock options in Regeneron Pharmaceuticals.

Director Kathryn Guarini reports acquisition of restricted stock units and stock options in Regeneron Pharmaceuticals.

Director Joseph L. Goldstein reports acquisition of Regeneron stock and options via restricted stock units and non-qualified stock options.

Director Michael S. Brown reports acquisition of Regeneron stock and stock options.

Director Bonnie L. Bassler reports acquisition of Regeneron stock and options.

Director George L. Sing reports acquisition and disposal of Regeneron Pharmaceuticals stock and stock options on December 31, 2024, and January 2, 2025.

Daniel P. Van Plew, EVP & General Manager at Regeneron Pharmaceuticals, sold 969 shares of common stock on December 16, 2024, to cover tax obligations.

Neil Stahl, EVP of Research and Development at Regeneron Pharmaceuticals, disposed of 304 shares of common stock on December 16, 2024, to cover tax obligations.

Jason Pitofsky, VP Controller at Regeneron Pharmaceuticals, reports the disposal of 298 shares of common stock to cover tax obligations.

Andrew Murphy, EVP of Research at Regeneron Pharmaceuticals, reported the disposition of 1,054 shares of common stock to cover tax obligations, while also holding shares indirectly through a 401(k) plan.

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, disposed of 759 shares of common stock on December 16, 2024, to cover tax obligations.

Joseph LaRosa, EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, reports the disposition of 702 shares of common stock to cover tax obligations.

Christopher R. Fenimore, SVP Finance & CFO of Regeneron Pharmaceuticals, reports disposing of 491 shares of common stock to cover tax obligations.

Regeneron's VP Controller, Jason Pitofsky, reports the acquisition of restricted stock and stock options, along with the disposal of shares to cover tax obligations.

Regeneron's CFO, Christopher R. Fenimore, reported the acquisition of restricted stock and stock options, as well as the disposal of shares to cover tax obligations.

Regeneron's Executive Vice President of Research and Development, Neil Stahl, sold 466 shares of company stock to cover tax obligations.

Regeneron Pharmaceuticals executive Daniel P. Van Plew reports acquisition of restricted stock and stock options, along with disposition of shares to cover tax obligations.

Regeneron's EVP of Research, Andrew Murphy, reports the acquisition of restricted stock and stock options, as well as the disposal of shares to cover tax obligations.